One of Abbott's systems was Lingo, and the second system, called Libre Rio, is intended for patients with Type 2 diabetes who do not take insulin. Though Type 2 patients who are not taking insulin ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

CEO Robert Ford said in an earnings call in October that the potential for Abbott's FreeStyle Libre CGM is a “mass market opportunity.” There are about 10 million CGM users worldwide ...

Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory ... despite softness in its international pediatric segment, Abbott is regaining market share banking on a strong ...